OTHER DEFENDANTS!!

CloudMinds was founded in 2015 and is backed by SoftBank, Foxconn, Walden Venture Investments, and Keytone Ventures.[1] CloudMinds has developed research in smart devices, robot control, high-speed security networks, and cloud intelligence integration.

Lockheed Martin is enhancing commercially available 5G and Next G technology with military-grade network and transmission security features while leveraging the global reach of commercial infrastructure to expand access to a worldwide network.

10 Best gene-editing Stocks to Invest in 2023

This guide presents the 10 best gene-editing stocks for solid long-term gains, looking at which companies stand to benefit the most from growth in the sector.

  1. CRISPR Therapeutics: The mid-cap clinical-stage biotech company has seen its shares soar more than 30% to start this month. CrisprTherapeutics (NASDAQ: CRSP), which as the name suggests, focuses on CRISPR gene-editing solutions, doesn’t have any approved therapies, but it does have more than $1.7 billion in cash as of the third quarter, plenty to get exa-cel to the finish line and help market it. It also has other early stage programs in its pipeline, including blood cancer therapies CTX110 and CTX130.
  2. Intellia Therapeutics: This mid-cap clinical-stage gene-editing company also uses CRISPR gene editing. Intellia (NASDAQ: NTLA), has  a lead therapy, NTLA-201, that it is developing in a partnership with Regeneron Pharmaceuticals (NASDAQ: REGN). NTLA-201 is being tested to treat transthyretin amyloidosis with cardiomyopathy, a rare progressive genetic disease that is usually fatal. The company got approval from the FDA last month to launch a phase 3 trial in NTLA-201. 
  3. Vertex Pharmaceuticals: This large-cap biotech company has seen its shares jump by more than 8% this month, thanks to the news regarding exa-cel. The company already is on strong financial ground, thanks to its dominance in cystic fibrosis therapies. It also has a promising non-opioid painkiller, VX-548, in its growing pipeline.
  4. Beam Therapeutics: The small-cap clinical-stage biotech company’s shares are up more than 30% since the month started. One thing that separates Beam (NASDAQ: BEAM) is its base gene editing, considered a more precise form of genetic editing, with possibly fewer side effects. Beam’s lead programs to treat SCD and  alpha-1 antitrypsin deficiency (AATD), a genetic condition that causes lung and liver damage, are in the early stages. 
  5. Bluebird Bio: The small-cap biotech already has two approved therapies. Zynteglo is designed to treat TDT and Skysona is approved to treat cerebral adrenoleukodystrophy (CALD), a progressive neurodegenerative disease that affects children, causing damage to the myelin sheaths in the brain and spinal cord. The big catalyst for Bluebird (NASDAQ: BLUE), though, will be if lovo-cel gets the go-ahead from the FDA on Dec. 20 to treat SCD. ICER said that like exa-cel, lovo-cel would be worth between $1.35 million and $2.05 million per treatment. 
  6. Agilent Technologies: The large-cap life services company didn’t get much of a bump from the positive gene-editing news, with its shares up only 7% so far in November. Agilent (NYSE: A) isn’t a pure-play gene editing stock because it makes materials that gene-editing companies use, including CRISPR bioreagents, next-generation sequencing library prep and sample quality control. 
  7. Caribou Biosciences: The small-cap clinical-stage biotech company’s shares are up more than 15% so far this month. Caribou (NASDAQ: CRBU) has the backing of Pfizer (NYSE: PFE), which recently bought $25 million shares of the biotech company. Caribou focuses on off-the-shelf CAR-T and CAR-NK cell therapies. The company has three pipeline therapies that are in early trials, including CB-010 to treat B-cell Non-Hodgkin Lymphoma. CB-10 has Fast Track, Regenerative Medicine Advanced Therapy and Orphan Drug designations from the FDA. There’s also CB-011, which received Fast Track Designation from the FDA as a therapy to treat relapsed or refractory multiple myeloma, a cancer that forms in plasma cells, and CB-012, which is being examined to treat acute myeloid leukemia.
  8. Regeneron Pharmaceuticals: The large-cap biotech company has several marketed products and a deep pipeline of more than 35 programs. The company is another stock that benefits from its gene-editing adjacency status, as it partners with gene-editing companies to complement its portfolio. Regeneron (NASDAQ: REGN) is working with Intellia Therapeutics on in vivo CRISPR-based gene editing therapies to treat neurological and muscular diseases. Regeneron also just bought Decibel Therapeutics (NASDAQ: DBTX), which it already had ongoing collaborations with, on gene therapy programs to target hearing loss.
  9. Gilead Sciences: The large-cap pharmaceutical company, best known for its antiviral treatments for HIV and hepatitis, has several gene-editing collaborations with other companies as a way to find better oncology therapies. The company has a huge pipeline, including eight cell therapies.
  10. Twist Bioscience: The small-cap biotech company is gene-editing adjacent as it has a DNA synthesis platform that is used by gene-editing companies. Shares for Twist (NASDAQ: TWST) are up more than 13% so far this month.

https://www.techopedia.com/investing/best-gene-editing-stocks

Article I, Section 4, Clause 1:

The Times, Places and Manner of holding Elections for Senators and Representatives, shall be prescribed in each State by the Legislature thereof; but the Congress may at any time by Law make or alter such Regulations, except as to the Places of chusing Senators.

By its terms, Article I, Section 4, Clause 1, referred to as the Elections Clause, contemplates that state legislatures will establish the times, places, and manner of holding elections for the House of Representatives and the Senate, subject to Congress making or altering such state regulations (except as to the place of choosing Senators).1 The Supreme Court has interpreted the Elections Clause expansively, enabling states to provide a complete code for congressional elections, not only as to times and places, but in relation to notices, registration, supervision of voting, protection of voters, prevention of fraud and corrupt practices, counting of votes, duties of inspectors and canvassers, and making and publication of election returns

TRANSNATIONAL CRIMINAL BIOWEAPONS INFLITRATED THE U.S. GOVERNMENT- NATIONAL EMERGENCY TEMPORARY SUSPENDING ELECTIONS RESTRAING ORDER ON 2024 PRESIDENTIAL ELECTIONS

RETROACTIVE ADJUDICATION AND DECLARATORY JUDGMENT THAT ALL TANGIBLE AND INTANGIBLE PROPERTY OF THE DEFENDANTS(FROM JAN. 1, 1993 AND CONTINUING THRU TO PRESENT)IS THE PLAINIFF AND/OR CLAIM!!

IT IS RETROACTIVELY AJDUDICATED THAT ORDERED, AJDUDICATED AND DECREED THAT “THE 50 STATES” EX REL PRIVATE ATTORNEY GENERAL AND/OR QUI TAM RELATOR IS THE OWNER OF ALL CENTRAL BANKS AND “BANK-FORCLOSED REAL ESTATE.” ANY AND ALL REAL ESTATE CONTRACTS ARE NULL AND VOID ALL CONTRACTS MUST BE NEGOITATE WITH THE “50 STATE”

IN FURTHERANCE OF THE CONSPIRACY TO RESTRAIN COMMERCE DEFRAUD TWO MINORITY BUSINESS “FORMER REAL ESTATE OWNERS” GRANT CHINA SUPREME AUTHORITY OVER THE U.S.A. AND THE TWO WITNESS ALL DEFENDANTS USE OTHER OPTIONS TO DEFRAUD THE U.S.A. AND RESTRAIN COMMERCE AND GRANT CHINA SUPREME AUTHORITY OVER THE U.S.A. BY BUYING MASS REAL ESTATE AND MORE FARM LAND IN THE U.S.A.(VIOLATIONS OF THE SHERMAN ACT)ALL SINGLE FAMILY HOMES, APARTMENT BUILDINGS, RENTAL HOUSING, Logistics, hospitality, lab offices, data centers, Real Estate Crowdfunding,  Real Estate Trust Investments (REITs), COMMERCIAL REAL ESTATE “ALL REAL ESTATE” PURCHASE ARE NULL AND VOID AND CONSTITUTE A SCHEME TO DEFRAUD THE U.S.A. POOL RESOURCES TO BUY PO

search previous next tag category expand menu location phone mail time cart zoom edit close